Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. India
  4. NSE India Stock Exchange
  5. Cadila Healthcare Limited
  6. Summary
    CADILAHC   INE010B01027

CADILA HEALTHCARE LIMITED

(CADILAHC)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nse India Stock Exchange
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
534.3(c) 527.1(c) 517.2(c) 510.6(c) 502.4(c) Last
1 547 343 1 285 363 1 159 491 1 131 700 1 113 599 Volume
-1.80% -1.35% -1.88% -1.28% -1.61% Change
More quotes
Estimated financial data (e)
Sales 2022 160 B 2 139 M 2 139 M
Net income 2022 26 954 M 359 M 359 M
Net Debt 2022 24 297 M 324 M 324 M
P/E ratio 2022 23,3x
Yield 2022 0,86%
Sales 2023 173 B 2 311 M 2 311 M
Net income 2023 24 456 M 326 M 326 M
Net Debt 2023 10 256 M 137 M 137 M
P/E ratio 2023 21,0x
Yield 2023 0,91%
Capitalization 514 B 6 861 M 6 859 M
EV / Sales 2022 3,36x
EV / Sales 2023 3,03x
Nbr of Employees 24 412
Free-Float 25,1%
More Financials
Company
Cadila Healthcare Limited is an India-based pharmaceutical company. The Company's subsidiaries include Zydus Wellness Limited, Windlas Healthcare Pvt Ltd, Liva Pharmaceuticals Limited, Biochem Pharmaceutical Industries Limited, Zydus Technologies Limited, German Remedies Limited, Dialforhealth India Limited, Dialforhealth Unity Limited and Dialforhealth Greencross Limited, among others. 
Sector
Pharmaceuticals
Calendar
11/17Earnings Release
More about the company
Ratings of Cadila Healthcare Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about CADILA HEALTHCARE LIMITED
10/22CADILA HEALTHCARE : Zydus announces ‘first patient' randomised in EVIDENCES-X TM Pha..
PU
10/22Zydus Announces First Patient' Randomised in Evidences-X Phase II(B) Clinical Trial of ..
CI
10/09CADILA HEALTHCARE : Fortress Biotech and Cyprium Therapeutics Announce Positive Clinical D..
PU
10/08CADILA HEALTHCARE : Zydus Cadila receives tentative approval from USFDA for Adapalene and ..
PU
10/08CADILA HEALTHCARE : Gets US FDA's Tentative Nod for Acne Treatment Drug
MT
10/08Zydus Cadila receives tentative approval from USFDA for Adapalene and Benzoyl Peroxide ..
CI
09/24India's Shilpa Medicare to produce Cadila's COVID-19 shot
RE
09/24India's Shilpa Medicare to produce Cadila's COVID-19 shot
RE
09/24SHILPA MEDICARE : Biologics Unit Partners with Cadila Healthcare for Supply of COVID-19 Dr..
MT
09/24CADILA HEALTHCARE : Zydus Cadila receives final approval from USFDA for Apremilast Tablets
PU
09/24SHILPA MEDICARE : to make Cadila's COVID-19 shot
RE
09/24Shilpa Medicare Limited Ties Up with Cadila Healthcare Ltd for Production of Zycov-D Va..
CI
09/24CADILA HEALTHCARE : Unit Gets US FDA's Nod for Plaque Psoriasis Drug
MT
09/22CADILA HEALTHCARE : India to target children for COVID-19 vaccine from Oct -sources
RE
09/20CADILA HEALTHCARE : Subsidiary Signs Pact to Sell Two Brands to Integrace
MT
More news
News in other languages on CADILA HEALTHCARE LIMITED
10/08Cadila Healthcare obtient l'accord provisoire de la FDA pour un médicament contre l'acn..
09/24L'unité de produits biologiques de Shilpa Medicare s'associe à Cadila Healthcare pour l..
09/24L'unité de Cadila Healthcare obtient le feu vert de la FDA pour un médicament contre le..
09/20La filiale de Cadila Healthcare signe un pacte pour vendre deux marques à Integrace
09/19Cadila Healthcare obtient le feu vert de la FDA pour un médicament antidépresseur
More news
Chart CADILA HEALTHCARE LIMITED
Duration : Period :
Cadila Healthcare Limited Technical Analysis Chart | CADILAHC | INE010B01027 | MarketScreener
Technical analysis trends CADILA HEALTHCARE LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Last Close Price 502,40 INR
Average target price 596,96 INR
Spread / Average Target 18,8%
EPS Revisions
Managers and Directors
Sharvil Pankajbhai Patel Managing Director & Executive Director
Nitin Dalsukhrai Parekh Chief Financial Officer
Pankaj Ramanbhai Patel Non-Executive Chairman
Ganesh Narayan Nayak Chief Operating Officer & Executive Director
Dhaval N. Soni Secretary & Compliance Officer